Immune Reconstitution Inflammatory Syndrome and Hodgkin’s Lymphoma

AUTOIMMUNE THROMBOCYTOPENIA

AV Pivnik1, AM Vukovich2, AA Petrenko3,4

1 SM Clinic, 42 bld. 12 Volgogradskii pr-t, Moscow, Russian Federation, 109548

2 IM Sechenov First Moscow State Medical University, 8 bld. 2 Trubetskaya str., Moscow, Russian Federation, 119991

3 SP Botkin Municipal Clinical Hospital, 5 2-i Botkinskii pr-d, Moscow, Russian Federation, 125284

4 Russian Medical Academy of Postgraduate Education, 2/1 Barrikadnaya str., Moscow, Russian Federation, 125993

For correspondence: Prof. Aleksandr Vasilevich Pivnik, MD, PhD, 42 bld. 12 Volgogradskii pr-t, Moscow, Russian Federation, 109548; Tel.: +7(906)065-99-32; e-mail: pivnikav@gmail.com

For citation: Pivnik AV, Vukovich AM, Petrenko AA. Immune Reconstitution Inflammatory Syndrome and Hodgkin’s Lymphoma. Clinical oncohematology. 2021;14(3):378–85. (In Russ).

DOI: 10.21320/2500-2139-2021-14-3-378-385

ABSTRACT

Immune reconstitution inflammatory syndrome (IRIS) is defined as a clinically significant exacerbation of known oligosymptomatic serious, more often infectious, diseases with considerably increased CD4+ T-lymphocyte count in response to highly active anti-retroviral therapy (HAART) of HIV infection. The review comprehensively discusses tuberculosis issues in HIV-positive HAART recipients. Related recommendations contain strict guidelines on compulsory treatment of tuberculosis prior to HAART assignment. Similar recommendations for specific therapy preceding HAART are provided for other opportunistic infections (mycotic and cryptococcal infections, parasitosis, molluscum contagiosum, toxoplasmosis, herpes-zoster virus, leishmaniasis, syphilis, and lepra). Without prior specific therapy of an opportunistic infection its exacerbation with pronounced symptoms and signs on HAART can be fatal for the patient. Lymphomas including Hodgkin’s lymphoma (HL) are dealt with in the context of the same challenge. However, what remains unclear is the specificity of targeted T-lymphocytes in the microenvironment to hitherto unclarified cause-specific antigens of the tumor. As opposed to other malignant lymphoid tumors arising with low level of CD4+ T-lymphocytes, HL develops when the level of CD4+ T-lymphocytes is increased in response to HAART in HIV-positive patients during the first months of anti-retroviral therapy. HL is diagnosed in 8 % of HIV-positive off-HAART subjects. After HAART assignment the HL incidence goes up to 17 %. Therefore, IRIS can be considered the main challenge in the study of etiology and pathogenesis of HL in HIV-positive patients. In this context, the demand to extend the research in this field becomes not only obvious but crucial for practical applications.

Keywords: immune reconstitution inflammatory syndrome (IRIS), highly active anti-retroviral therapy (HAART), Hodgkin’s lymphoma.

Received: January 19, 2021

Accepted: April 22, 2021

Read in PDF

Статистика Plumx английский

REFERENCES

  1. Fanales-Belasio E, Raimondo M, Suligoi B, Butto S. HIV virology and pathogenetic mechanisms of infection: a brief overview. Ann Ist Super Sanita. 2010;46(1):5–14. doi: 10.4415/ANN_10_01_02.
  2. Turner BG, Summers MF. Structural biology of HIV1. J Mol Biol. 1999;285(1):1–32. doi: 10.1006/jmbi.1998.2354.
  3. Richman DD, Little SJ, Smith DM, et al. HIV evolution and escape. Trans Am Clin Climatol Assoc. 2004;115:289–303.
  4. Zhu T, Korber BT, Nahmias AJ, et al. An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature. 1998;391(6667):594–7. doi: 10.1038/35400.
  5. Sophie G, Thomas DW, Kabongo J-M, et al. A near full-length HIV-1 genome from 1966 recovered from formalin-fixed paraffin-embedded tissue. Proc Nat Acad Sci USA. 2020;117(22):12222–9. doi: 10.1073/pnas.1913682117.
  6. Klatt NR, Silvestri G, Hirsch V. Non pathogenic simian immunodeficiency virus infections. Cold Spring Harb Perspect Med. 2012;2(1):a007153. doi: 10.1101/cshperspect.a007153.
  7. Sharp PM, Hahn BH. Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med. 2011;1(1):a006841. doi: 10.1101/cshperspect.a006841.
  8. Chitnis A, Rawls D, Moore J. Origin of HIV Type 1 in Colonial French Equatorial Africa? AIDS Res Hum Retrovir. 2000;16(1):5–8. doi: 10.1089/088922200309548.
  9. Gao F, Bailes E, Robertson DL, et al. Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. Nature. 1999;397(6718):436–41. doi: 10.1038/17130.
  10. Haverkos HW, Curran JW. The Current Outbreak of Kaposi’s Sarcoma and Opportunistic Infections. CA: Cancer J Clin. 1982;32(6):330–9. doi: 10.3322/canjclin.32.6.330.
  11. Gallo RC, Sarin PS, Gelmann EP, et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science. 1983;220(4599):865–7. doi: 10.1126/science.6601823.
  12. Barre-Sinoussi F, Chermann J, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983;220(4599):868–71. doi: 10.1126/science.6189183.
  13. Pincock S. HIV discoverers awarded Nobel Prize for medicine. Lancet. 2008;372(9647):1373. doi: 10.1016/s0140-6736(08)61571-8.
  14. The Nobel Prize. Available from: https://www.nobelprize.org/prizes/medicine/2008/press-release/ (accessed 13.04.2021).
  15. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382(6593):722–5. doi: 10.1038/382722a0.
  16. Galvani AP, Novembre J. The evolutionary history of the CCR5-Delta32 HIV-resistance mutation. Microbes Infect. 2005;7(2):302–9. doi: 10.1016/j.micinf.2004.12.006.
  17. Ni J, Wang D, Wang S. The CCR5-Delta32 Genetic Polymorphism and HIV-1 Infection Susceptibility: a Meta-analysis. Open Med (Wars). 2018;13(1):467–74. doi: 10.1515/med-2018-0062.
  18. Stephens JC, Reich DE, Goldstein DB, et al. Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet. 1998;62(6):1507–15. doi: 10.1086/301867.
  19. Hopkins Princes and Peasants: Smallpox in History. Chicago: University of Chicago Press; 1983. 380 p.
  20. Galvani AP, Slatkin M. Evaluating plague and smallpox as historical selective pressures for the CCR5-Delta 32 HIV-resistance allele. Proc Natl Acad Sci USA. 2003;100(25):15276–9. doi: 10.1073/pnas.2435085100.
  21. Brown TR. I am the Berlin patient: a personal reflection. AIDS Res Hum Retrovir. 2015;31(1):2–3. doi: 10.1089/AID.2014.0224.
  22. Gallagher J. Berlin patient: First person cured of HIV, Timothy Ray Brown, dies. Available from: https://www.bbc.com/news/health-54355673. (accessed 13.04.2021).
  23. Gupta RK, Peppa D, Hill AL, et al. Evidence for HIV-1 cure after CCR5Δ32/Δ32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report. Lancet HIV. 2020;7(5):340–7. doi: 10.1016/S2352-3018(20)30069-2.
  24. Normile D. Shock greets claim of CRISPR-edited babies. Science. 2018;362(6418):978–9. doi: 10.1126/science.362.6418.978.
  25. ВИЧ-инфекция и СПИД: национальное руководство. Под ред. В.В. Покровского. 2-е изд., перераб. и доп. М.: ГЭОТАР-Медиа, 2020. 696 с. doi: 10.33029/9704-5421-3-2020-VIC-1-696.
    [Pokrovsky VV, ed. VICh-infektsiya i SPID: natsionalnoe rukovodstvo. (HIV infection and AIDS: national guidelines.) 2nd edition, revised and enlarged. Moscow: GEOTAR-Media Publ.; 2020. 696 p. doi: 10.33029/9704-5421-3-2020-VIC-1-696. (In Russ)]
  26. ЮНЭЙДС. COVID-19 и ВИЧ [электронный документ]. Доступно по: https://www.unaids.org/ru. Ссылка активна на 04.2021.
    [UNAIDS. COVID-19 and HIV. [Internet] Available from: https://www.unaids.org/ru. (accessed 13.04.2021) (In Russ)]
  27. Peterman TA, Drotman DP, Curran JW. Epidemiology of the acquired immunodeficiency syndrome (AIDS). Epidemiol Rev. 1985;7(1):1–21. doi: 10.1093/oxfordjournals.epirev.a036277.
  28. Aliouat-Denis CM, Chabe M, Demanche C, et al. Pneumocystis species, co-evolution and pathogenic power. Infect Genet Evol. 2008;8(5):708–26. doi: 10.1016/j.meegid.2008.05.001.
  29. Giffin L, Damania B. KSHV: pathways to tumorigenesis and persistent infection. Adv Vir Res. 2014;88:111–59. doi: 10.1016/B978-0-12-800098-4.00002-7.
  30. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents. 2009;33(4):307–20. doi: 10.1016/j.ijantimicag.2008.10.010.
  31. Леви Д.Э. ВИЧ и патогенез СПИДа. 3-е издание. Пер. с англ. Е.А. Монастырской. М.: Научный мир, 2010. 736 с.
    [Levy JA. HIV and the pathogenesis of AIDS, 3rd edition. Wiley; 2007. 752 p. (Russ. transl.: Monastyrskaya EA. VICh i patogenez SPIDa. 3-e izdanie. Moscow: Nauchnyi mir Publ.; 2010. 736 p.)]
  32. Pau AK, George JM. Antiretroviral therapy: current drugs. Infect Dis Clin North Am. 2014;28(3):371–402. doi: 10.1016/j.idc.2014.06.001.
  33. Lai RP, Meintjes G, Wilkinson RJ. HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome. Semin Immunopathol. 2016;38(2):185–98. doi: 10.1007/s00281-015-0532-2.
  34. Richter E, Wessling J, Lugering N, et al. Mycobacterium avium subsp. paratuberculosis infection in a patient with HIV, Germany. Emerg Infect Dis. 2002;8(7):729–31. doi: 10.3201/eid0807.010388.
  35. Amerson EH, Maurer TA. Immune Reconstitution Inflammatory Syndrome and Tropical Dermatoses. Dermatol Clin. 2011;29(1):39–43. doi: 10.1016/j.det.2010.09.007.
  36. Gupta A, Sharma YK, Ghogre M, et al. Giant molluscum contagiosum unmasked probably during an immune reconstitution inflammatory syndrome. Indian J Sex Transm Dis AIDS. 2018;39(2):139–40. doi: 10.4103/ijstd.IJSTD_60_16.
  37. Balasko A, Keynan Y. Shedding light on IRIS: from Pathophysiology to Treatment of Cryptococcal Meningitis and Immune Reconstitution Inflammatory Syndrome in HIV-Infected Individuals. HIV Med. 2019;20(1):1–10. doi: 10.1111/hiv.12676.
  38. Martin-Blondel G, Alvarez M, Delobel PV, et al. Toxoplasmic encephalitis IRIS in HIV-infected patients: a case series and review of the literature. J Neurol Neurosurg Psych. 2010;82(6):691–3. doi: 10.1136/jnnp.2009.199919.
  39. Karavellas MP, Lowder CY, Macdonald C, et al. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol. 1998;116(2):169–75. doi: 10.1001/archopht.116.2.169.
  40. Boulougoura A, Sereti I. HIV infection and immune activation: the role of coinfections. Curr Opin HIV AIDS. 2016;11(2):191–200. doi: 10.1097/COH.0000000000000241.
  41. Hosoda T, Uehara Y, Kasuga K, et al. An HIV-infected patient with acute retinal necrosis as immune reconstitution inflammatory syndrome due to varicella-zoster virus. AIDS. 2020;34(5):795–6. doi: 10.1097/QAD.0000000000002477.
  42. Auyeung P, French MA, Hollingsworth PN. Immune Restoration Disease Associated with Leishmania donovani Infection Following Antiretroviral Therapy for HIV Infection. J Microbiol Immunol Infect. 2010;43(1):74–6. doi: 10.1016/S1684-1182(10)60011-4.
  43. Alcedo S, Newby R, Montenegro J, et al. Immune reconstitution inflammatory syndrome associated with secondary syphilis: dermatologic, neurologic and ophthalmologic compromise in an HIV patient. Int J STD AIDS. 2019;30(5):509–11. doi: 10.1177/0956462418813045.
  44. Mathukumalli NL, Ali N, Kanikannan MA, Yareeda S. Worsening Guillain-Barre syndrome: harbinger of IRIS in HIV? BMJ Case Rep. 2017;2017:bcr-2017-221874. doi: 10.1136/bcr-2017-221874.
  45. Weetman A. Immune reconstitution syndrome and the thyroid. Best Pract Res Clin Endocrinol Metabol. 2009;23(6):693–702. doi: 10.1016/j.beem.2009.07.003.
  46. DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory Reactions in HIV-1–Infected Persons after Initiation of Highly Active Antiretroviral Therapy. Ann Intern Med. 2000;133(6):447–54. doi: 10.7326/0003-4819-133-6-200009190-00013.
  47. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8(8):516–23. doi: 10.1016/s1473-3099(08)70184-1.
  48. Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother. 2005;57(2):167–70. doi: 10.1093/jac/dki444.
  49. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS. 2004;18(12):1615–27. doi: 10.1097/01.aids.0000131375.21070.06.
  50. Lai RPJ, Nakiwala JK, Meintjes G, Wilkinson RJ. The immunopathogenesis of the HIV tuberculosis immune reconstitution inflammatory syndrome. Eur J Immunol. 2013;43(8):1995–2002. doi: 10.1002/eji.201343632.
  51. Improving the diagnosis and treatment of smear-negative pulmonary and extrapulmonary tuberculosis among adults and adolescents: recommendations for HIV-prevalent and resource-constrained settings. Geneva: Stop TB Department, Department of HIV/AIDS, World Health Organization; 2006.
  52. Manosuthi W, Kiertiburanakul S, Phoorisri T, Sungkanuparph S. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect. 2006;53(6):357–63. doi: 10.1016/j.jinf.2006.01.002.
  53. Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS. 2007;21(3):335–41. doi: 10.1097/QAD.0b013e328011efac.
  54. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med. 1998;158(1):157–61. doi: 10.1164/ajrccm.158.1.9712001.
  55. Breen RA, Smith CJ, Bettinson H, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV co-infection. Thorax. 2004;59(8):704–7. doi: 10.1136/thx.2003.019224.
  56. Breton G, Duval X, Estellat C, et al. Determinants of Immune Reconstitution Inflammatory Syndrome in HIV Type 1-Infected Patients with Tuberculosis after Initiation of Antiretroviral Therapy. Clin Infect Dis. 2004;39(11):1709–12. doi: 10.1086/425742.
  57. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS. 2010;24(15):2381–90. doi: 10.1097/QAD.0b013e32833dfc68.
  58. Michailidis C, Pozniak AL, Mandalia S, et al. Clinical characteristics of IRIS syndrome in patients with HIV and tuberculosis. Antivir Ther. 2005;10(3):417–22.
  59. Chang CC, Dorasamy AA, Gosnell BI, et al. Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome. AIDS. 2013;27(13):2089–99. doi: 10.1097/qad.0b013e3283614a8d.
  60. Sereti Immune reconstruction inflammatory syndrome in HIV infection: beyond what meets the eye. Top Antivir Med. 2020;27(4):106–11.
  61. Jenny-Avital ER, Abadi Immune Reconstitution Cryptococcosis after Initiation of Successful Highly Active Antiretroviral Therapy. Clin Infect Dis. 2002;35(12):128–33. doi: 10.1086/344467.
  62. Somnuek S, Scott GF, Ploenchan C, et al. Cryptococcal Immune Reconstitution Inflammatory Syndrome after Antiretroviral Therapy in AIDS Patients with Cryptococcal Meningitis: A Prospective Multicenter Study. Clin Infect Dis. 2009;6(15):931–4. doi: 10.1086/605497.
  63. Meya DB, Okurut S, Zziwa G, et al. HIV-Associated Cryptococcal Immune Reconstitution Inflammatory Syndrome Is Associated with Aberrant T Cell Function and Increased Cytokine Responses. J Fungi. 2019;5(2):42. doi: 10.3390/jof5020042.
  64. Arevalo JF, Mendoza AJ, FerrettiI Y. Immune Recovery Uveitis In AIDS Patients With Cytomegalovirus Retinitis Treated With Highly Active Antiretroviral Therapy In Venezuela. Retina. 2003;23(4):495–502. doi: 10.1097/00006982-200308000-00009.
  65. Jabs DA. Cytomegalovirus retinitis and the acquired immunodeficiency syndrome—bench to bedside: LXVII Edward Jackson Memorial Lecture. Am J Ophthalmol. 2011;151(2):198–216. doi: 10.1016/j.ajo.2010.10.018.
  66. Kaplan JE, Benson C, Holmes KK, et al; Centers for Disease Control and Prevention (CDC). Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America, National Institutes of Health, HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm. 2009;58(RR-4):1–207. doi: 10.1037/e537722009-001.
  67. Jacobson MA, Zegans M, Pavan P. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet. 1997;349(9063):1443–5. doi: 10.1016/s0140-6736(96)11431-8.
  68. Mitchell SM, Membrey WL, Youle MS, et al. Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: a 2 year prospective study. Br J Ophthalmol. 1999;83(6):652–5. doi: 10.1136/bjo.83.6.652.
  69. Jabs DA, Ahuja A, Van Natta M, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomes. Ophthalmology. 2010;117(11):2152–2161.е2. doi: 10.1016/j.ophtha.2010.03.031.
  70. Матиевская Н.В. Воспалительный синдром восстановления иммунитета у ВИЧ-инфицированных пациентов: факторы риска, клинические проявления, исходы, профилактика. Вестник Балтийского федерального университета им. И. Канта. 2012;7:44–51.
    [Matievskaya NV. Immune reconstitution inflammatory syndrome: risk factors, clinical manifestations, outcomes, prevention. Vestnik Baltiiskogo federal’nogo universiteta im. I. Kanta. 2012;7:44–51. (In Russ)]
  71. Пантелеев А.М. Патогенез, клиника, диагностика и лечение туберкулеза у больных ВИЧ-инфекцией: Дис.… д-ра мед. наук. СПб., 2012. 236 с.
    [Panteleev AM. Patogenez, klinika, diagnostika i lechenie tuberkuleza u bol’nykh VICh-infektsiei. (Pathogenesis, clinical features, diagnosis, and treatment of tuberculosis in patients with HIV infection.) [dissertation] Petersburg; 2012. 236 p. (In Russ)]
  72. Битнева А.М., Козлова Т.П., Савинцева Е.В. Особенности начала и течения синдрома восстановления иммунитета у больных туберкулезом легких. Проблемы науки. 2017;6(19):104–5.
    [Bitneva AM, Kozlova TP, Savintseva EV. Characteristics of the start and course of immune reconstitution inflammatory syndrome in pulmonary tuberculosis. Problemy nauki. 2017;6(19):104–5. (In Russ)]
  73. ТищенкоТ.В., Цыркунов В.М. Воспалительный синдром восстановления иммунитета у ВИЧ-инфицированных пациентов: клинико-морфологические аспекты. Здравоохранение (Минск). 2017;10:5–11.
    [Tishchenko TV, Tsyrkunov VM. Immune reconstitution inflammatory syndrome in HIV-positive patients: clinicopathologic Zdravookhranenie (Minsk). 2017;10:5–11. (In Russ)]
  74. Улюкин И.М. ВИЧ-инфекция: особенности восстановления иммунной системы на фоне специфической терапии туберкулеза. Клиническая патофизиология. 2017;23(2):29–33.
    [Ulyukin IM. HIV-infection: characteristics of immune reconstitution on specific therapy of tuberculosis. Klinicheskaya patofiziologiya. 2017;23(2):29–33. (In Russ)]
  75. Sun H-Y, Singh N. Immune reconstitution inflammatory syndrome in non-HIV immunocompromised patients. Curr Opin Infect Dis. 2009;22(4):394–402. doi: 10.1097/QCO.0b013e32832d7aff.
  76. Vishnu P, Dorer RP, Aboulafia DM. Immune reconstitution inflammatory syndrome-associated Burkitt lymphoma after combination antiretroviral therapy in HIV-infected patients. Clin Lymphoma Myel Leuk. 2015;15(1):23–9. doi: 10.1016/j.clml.2014.09.009.
  77. Serraino D, Boschini A, Carrieri P, et al. Cancer risk among men with, or at risk of, HIV infection in southern Europe. AIDS. 2000;14(5):553–9. doi: 10.1097/00002030-200003310-00011.
  78. Noy A. Update on HIV lymphoma. Curr Oncol Rep. 2007;9(5):384–90. doi: 10.1007/s11912-007-0052-x.
  79. Franceschi S, Dal Maso L, Pezzotti P, et al. Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986–1998. J Acquir Immune Defic Syndr. 2003;34(1):84–90. doi: 10.1097/00126334-200309010-00013.
  80. Carbone A, Gloghini A, Larocca LM, et al. Human immunodeficiency virus associated Hodgkin’s disease derives from post-germinal center B cells. Blood. 1999;93(7):2319–26. doi: 10.1182/blood.V93.7.2319.
  81. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108(12):3786–91. doi: 10.1182/blood-2006-05-024109.
  82. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980–2002. AIDS. 2006;20(12):1645–54. doi: 10.1097/01.aids.0000238411.75324.59.
  83. Dauby N, De Wit S, Delforge M, et al. Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study. J Int AIDS Soc. 2011;14(1):16. doi: 10.1186/1758-2652-14-16.
  84. Stein H, Mann R, Delsol G, et al. Hodgkin lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001. рр. 237–52.
  85. Lanoy E, Rosenberg PS, Fily F, et al. HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapy. Blood. 2011;118(1):44–9. doi: 10.1182/blood-2011-02-339275.
  86. Bohlius J, Schmidlin K, Boue F, et al; Collaboration of Observational HIV Epidemiological Research Europe. HIV-1–related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes. 2011;117(23):6100–8. doi: 10.1182/blood-2010-08-301531.
  87. Kowalkowski MA, Mims MP, Amiran ES, et al. Effect of immune reconstitution on the incidence of HIV-related Hodgkin lymphoma. PloS One. 2013;8(10):e77409. doi: 10.1371/journal.pone.0077409.
  88. Kowalkowski MA, Mims MA, Day RS, et al. Longer duration of combination antiretroviral therapy reduces the risk of Hodgkin lymphoma: A cohort study of HIV-infected male veterans. Cancer Epidemiol. 2014;38(4):386–92. doi: 10.1016/j.canep.2014.05.009.
  89. Gotti D, Danesi M, Calabresi A, et al. Clinical Characteristics, Incidence, and Risk Factors of HIV-Related Hodgkin Lymphoma in the Era of Combination Antiretroviral Therapy. AIDS Patient Care STDs. 2013;27(5):259. doi: 10.1089/apc.2012.0424.
  90. Patel P, Hanson DL, Sullivan PS, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med. 2008;148(10):728–36. doi: 10.7326/0003-4819-148-10-200805200-00005.
  91. Yotsumoto M, Hagiwara S, Ajisawa A, et al. Clinical characteristics of human immunodeficiency virus-associated Hodgkin lymphoma patients in Japan. Int J Hematol. 2012;96(2):247–53. doi: 10.1007/s12185-012-1127-5.
  92. Sombogaard F, Franssen EJF, Terpstra WE. Outcome effects of antiretroviral drug combinations in HIV-positive patients with chemotherapy for lymphoma: a retrospective analysis. Int J Clin Pharm. 2018;40(5):1402–8. doi: 10.1007/s11096-018-0620-1.
  93. Eschke M, Piehler D, Schulze B, et al. A novel experimental model of Cryptococcus neoformans‐related immune reconstitution inflammatory syndrome (IRIS) provides insights into pathogenesis. Eur J Immunol. 2015;45(12):3339–50. doi: 10.1002/eji.201545689.
  94. Tadokera R, Wilkinson KA, Meintjes GA, et al. Role of the interleukin 10 family of cytokines in patients with immune reconstitution inflammatory syndrome associated with HIV infection and tuberculosis. J Infect Dis. 2013;207(7):1148–56. doi: 10.1093/infdis/jit002.
  95. Sereti I, Rodger AJ, French MA. Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis. Curr Opin HIV AIDS. 2010;5(6):504–10. doi: 10.1097/COH.0b013e32833ed774.
  96. Chang CC, Lim A, Omarjee S, et al. Cryptococcosis-IRIS is associated with lower cryptococcus-specific IFN-γ responses before antiretroviral therapy but not higher T-cell responses during therapy. J Infect Dis. 2013;208(6):898–906. doi: 10.1093/infdis/jit271.
  97. Meya DB, Manabe YC, Boulware DR, Janoff EN. The immunopathogenesis of cryptococcal immune reconstitution inflammatory syndrome: understanding a conundrum. Curr Opin Infect Dis. 2016;29(1):10–22. doi: 10.1097/QCO.0000000000000224.
  98. de Sa NBR, Ribeiro-Alves M, da Silva TP, et al. Clinical and genetic markers associated with tuberculosis, HIV-1 infection, and TB/HIV-immune reconstitution inflammatory syndrome outcomes. BMC Infect Dis. 2020;20(1):59. doi: 10.1186/s12879-020-4786-5.
  99. Crane M, Matthews G, Lewin SR. Hepatitis virus immune restoration disease of the liver. Curr Opin HIV AIDS. 2008;3(4):446–52. doi: 10.1097/coh.0b013e3282fdc953.
  100. Ravimohan S, Tamuhla N, Nfanyana K, et al. Robust Reconstitution of Tuberculosis-Specific Polyfunctional CD4+ T-Cell Responses and Rising Systemic Interleukin 6 in Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome. Clin Infect Dis. 2016;62(6):795–803. doi: 10.1093/cid/civ978.
  101. Stek C, Allwood B, Du Bruyn E, et al. The effect of HIV-associated tuberculosis, tuberculosis-IRIS and prednisone on lung function. Eur Respir J. 2020;55(3):1901692. doi: 10.1183/13993003.01692-2019.
  102. Dhasmana DJ, Dheda K, Ravn P, et al. Immune reconstitution inflammatory syndrome in HIV–infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs. 2008;68:191–208. doi: 10.2165/00003495-200868020-00004.
  103. Beishuizen SJ, Geerlings SE. Immune reconstitution inflammatory syndrome: immunopathogenesis, risk factors, diagnosis and prevention. Neth J Med. 2009;67(10):327–31.
  104. Herida A, Mary-Krause M, Kaphan R, et al. Incidence of non AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol. 2003;21(8):3447–53. doi: 10.1200/JCO.2003.01.096.
  105. Clifford GM, Polesel J, Rickenbach M, et al.; for the Swiss HIV Cohort. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97(6):425–32. doi: 10.1093/jnci/dji072.
  106. Stein H, Hummel M. Hodgkin’s disease: biology and origins of Hodgkin and Reed-Sternberg cells. Cancer Treat Rev. 1999;25(3):161–8. doi: 10.1053/ctrv.1999.0117.
  107. Chan The Reed-Sternberg cells in classical Hodgkin’s disease. Hematol Oncol. 2001;19(1):1–17. doi: 10.1002/hon.659.